natgillin/translations-raw huggingface dataset:
Pharmacokinetic studies in humans showed that the plasma concentration curve of cladribine fits a 2or 3-compartment model with - and β-half-lives of on average 35 minutes and 6.7 hours, respectively. 
Farmakokinetične študije pri človeku so pokazale, da krivulja plazemske koncentracije kladribina ustreza modelu z 2 ali 3 razdelki z - in β-razpolovnimi časi povprečno 35 minut oziroma 6,7 ur.
Clinical experience is very limited and safety of LITAK in these patients is not well established (see sections 4.3 and 5.2). 
Klinične izkušnje so zelo omejene, varnost zdravila LITAK pri teh bolnikih ni zadostno ugotovljena (glejte poglavji 4.3 in 5.2).
A daily oral dose of 100 mg of allopurinol is recommended for a period of 2 weeks. 
Priporočamo dnevni peroralni odmerek 100 mg alopurinola za obdobje 2 tednov.
Lymphocytopenia lasting for several months and immunosuppression with an increased risk of infections are expected. 
Pričakujemo limfocitopenijo, trajajočo več mesecev, in imunosupresijo s povečanim tveganjem za okužbe.
The recommended daily dose is 0.14 mg per kg body weight for five consecutive days (single treatment course). 
Priporočen dnevni odmerek je 0,14 mg na kg telesne mase na dan pet zaporednih dni (enkraten potek zdravljenja).
What LITAK is and what it is used for 
Kaj je zdravilo LITAK in za kaj ga uporabljamo
Non-haematologic tissues seem to be unaffected, explaining the low incidence of non-haematopoietic toxicity of cladribine 
Videti je, da nehematološka tkiva niso prizadeta, kar razlaga nizko pojavnost nehematopoetske toksičnosti kladribina.
Therapeutic risks and benefits should be carefully evaluated in patients with active or suspected infections. 
Tveganja in koristi zdravljenja je treba skrbno ovrednotiti pri bolnikih z aktivnimi okužbami ali s sumom na okužbo.
For all patients treated with LITAK, periodic assessment of renal and hepatic function is advised as clinically indicated. 
Za vse bolnike, zdravljene z zdravilom LITAK, se priporoča periodično ocenjevanje delovanja ledvic in jeter, kot je klinično indicirano.
Corticosteroids have been shown to enhance the risk for severe infections when used in combination with cladribine and should not be given concomitantly with cladribine. 
Za kortikosteroide so pokazali, da povečajo tveganje za hude okužbe, če jih uporabljamo v kombinaciji s kladribinom in jih ne smemo dajati sočasno s kladribinom.
Unlike other nucleoside analogues, cladribine is toxic in rapidly proliferating cells as well as in resting cells. 
Za razliko od drugih nukleozidnih analogov je kladribin toksičen v hitro proliferirajočih kot tudi mirujočih celicah.
In case of pregnancy during therapy with cladribine, the woman should be informed about the potential hazard to the foetus. 
V primeru zanositve v času zdravljenja s kladribinom moramo žensko obvestiti o možnem tveganju za plod.
The effects of cladribine on fertility have not been studied in animals. 
Učinkov kladribina na plodnost pri živalih niso preučevali.
At this dose, severe limb anomalies were seen as well as a significant decrease in the mean foetal weight. 
Pri tem odmerjanju so opažali hude anomalije okončin, pa tudi značilno znižanje povprečne telesne mase ploda.
If pregnancy occurs during your treatment, you must immediately inform your doctor. 
Če zanosite med zdravljenjem, morate nemudoma obvestiti svojega zdravnika.
At any time during or after your treatment, tell your doctor or nurse immediately if you: experience blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion. 
Če se kadar koli med zdravljenjem ali po njem pojavi kaj od naslednjega, o tem takoj obvestite zdravnika ali medicinsko sestro: zamegljen vid, izguba vida ali dvojni vid, težave pri govorjenju, oslabelost roke ali noge, sprememba načina hoje ali težave z ravnotežjem, dolgotrajna otrplost, zmanjšano zaznavanje ali izguba zaznavanja, izguba spomina ali zmedenost.
In particular, tell your doctor if you are using any medicines containing: - corticosteroids, commonly used to treat inflammation - antiviral agents, used to treat viral infections 
Zdravnika še zlasti obvestite, če uporabljate zdravila, ki vsebujejo: - kortikosteroide, ki se pogosto uporabljajo za zdravljenje vnetij - protivirusna zdravila, ki se uporabljajo za zdravljenje virustnih okužb
Progressive multifocal leukoencephalopathy (PML) Cases of PML, including fatal cases, have been reported with cladribine. 
Progresivna multifokalna levkoencefalopatija (PML) Pri zdravljenju s kladribinom so poročali o primerih PML, vključno s primeri, ki so se končali s smrtjo.
Severe long-term lymphocytopenias have been reported rarely which, however, could not be associated with late infectious complications. 
Poročali so o redkih hudih dolgotrajnih limfocitopenijah, ki pa jih ne moremo povezovati s poznimi zapleti zaradi okužbe.
If you are injecting LITAK yourself, first you must receive adequate training by your doctor or nurse. 
Če si zdravilo LITAK injicirate sami, vas mora najprej ustrezno poučiti zdravnik ali medicinska sestra.
Patients with symptoms of bone marrow depression should be treated with caution, since further suppression of bone marrow function should be anticipated. 
Bolnike s simptomi zavrtja delovanja kostnega mozga je treba zdraviti previdno, ker moramo predvideti nadaljnje zavrtje delovanja kostnega mozga.
Suggested evaluation for PML includes neurology consultation, magnetic resonance imaging of the brain, and cerebrospinal fluid analysis for JC virus (JCV) DNA by polymerase chain reaction (PCR) or a brain biopsy with testing for JCV. 
Predlagana diagnostika za PML vključuje nevrološko posvetovanje, magnetnoresonančno slikanje možganov in analizo cerebrospinalnega likvorja za DNA virusa JC (JCV) z verižno reakcijo s polimerazo (PCR-polymerase chain reaction) ali biopsijo možganov s preiskavo za JCV.
- a puncture-proof container for safe disposal of the used syringe. 
- vsebnik, odporen proti vbodom, za varno odlaganje uporabljene brizge.
10 ml type I glass vial with rubber stopper (bromobutyl) and flip-off aluminium cap. 
10 ml viala iz stekla tipa I z gumijastim zamaškom (bromobutil) in "flip-off" aluminijasto zaporko.
Adverse reactions related to skin and subcutaneous tissue are mostly mild or moderate and transient, usually resolving within a cycle interval of 30 days. 
Neželeni učinki, povezani s kožo in podkožjem, so večinoma blagi do zmerni in prehodni, običajno izzvenijo v cikličnem intervalu 30 dni.
Remove the needle guard without touching the needle. 
Snemite zaščito igle, ne da bi se igle dotaknili.
The highest incidence of second malignancy with LITAK was 6.5% after a median follow-up of 8.4 years. 
Najvišja pojavnost sekundarnih malignomov pri zdravilu LITAK je bila 6,5 % po medianem sledenju 8,4 let.
What you need to know before you use LITAK 
Kaj morate vedeti, preden boste uporabili zdravilo LITAK
It affects the growth of malignant (cancerous) white blood cells which play a role in hairy cell leukaemia. 
Vpliva na rast malignih (rakavih) belih krvničk, ki se pojavljajo pri dlakavocelični levkemiji.
Culture-negative fever following treatment with cladribine occurs in 10-40% of patients with hairy cell leukaemia and is rarely observed in patients with other neoplastic disorders. 
Zvišana telesna temperatura z negativnimi kulturami po zdravljenju s kladribinom se pojavlja pri 1040 % bolnikov z dlakavocelično levkemijo in jo le redko opažamo pri bolnikih z drugimi neoplastičnimi motnjami.
Very rare: amyloidosis 
Zelo redki: amiloidoza
From a microbiological point of view, unless the opening precludes the risk of microbiological contamination, the product should be used immediately. 
Z mikrobiološkega vidika je treba zdravilo uporabiti takoj, razen če metode odpiranja preprečijo mikrobiološo kontaminacijo.
Cladribine is contraindicated in pregnancy. 
Kladribin je v nosečnosti kontraindiciran.
Tell your doctor immediately if you have any of the following during or after treatment with LITAK: - any signs of infections (such as flu-like symptoms) - fever 
Svojega zdravnika nemudoma obvestite, če se med zdravljenjem z zdravilom LITAK ali po njem pojavi kaj od naslednjega: - kakršni koli znaki okužbe (kot so gripi podobni simptomi) - zvišana telesna temperatura
Cladribine is moderately acutely toxic to mice, with an LD50 of 150 mg/kg by intraperitoneal administration. 
Kladribin je zmerno akutno toksičen za miši, z LD50 150 mg/kg pri intraperitonealnem dajanju.
Pull slightly on the plunger to check that no blood vessel has been punctured. 
Rahlo potegnite za bat, da preverite, da niste vbodli v krvno žilo.
Due to the similar intracellular metabolism, cross-resistance with other nucleoside analogues, such as fludarabine or 2'-deoxycoformycin may occur. 
Zaradi podobne znotrajcelične presnove se lahko pojavi navzkrižna odpornost z drugimi nukleozidnimi analogi, kot sta fludarabin ali 2'-deoksikoformicin.
Fever of unknown origin frequently occurs in patients treated for hairy cell leukaemia and is manifested predominantly during the first 4 weeks of therapy. 
Zvišana telesna temperatura neznanega izvora se pogosto pojavlja pri bolnikih, zdravljenih zaradi dlakavocelične levkemije, in se kaže predvsem v prvih 4 tednih zdravljenja.
Although anti-infective prophylaxis is not generally recommended, it may be beneficial for patients immunocompromised prior to therapy with cladribine or for patients with a pre-existing agranulocytosis. 
Čeprav antiinfektivne profilakse v splošnem ne priporočamo, je lahko koristna za bolnike, imunsko kompromitirane pred zdravljenjem s kladribinom, ali za bolnike s predhodno agranulocitozo.
Rare serious adverse reactions 
Redki resni neželeni učinki
Paediatric population LITAK is contraindicated in patients less than 18 years of age (see section 4.3). 
Pediatrična populacija Uporaba zdravila LITAK je pri bolnikih, mlajših od 18 let, kontraindicirana (glejte poglavje 4.3).
In another study using a dose of 0.10 mg/kg body weight/day, the maximum plasma concentration Cmax after continuous intravenous infusion was 5.1 ng/ml (tmax: 12 hours) compared to 51 ng/ml after subcutaneous bolus injection (tmax: 25 minutes). 
V drugi študiji, kjer so uporabljali odmerek 0,10 mg/kg telesne mase/dan, je bila najvišja plazemska koncentracija Cmax po neprekinjeni intravenski infuziji 5,1 ng/ml (tmax: 12 ur) v primerjavi z 51 ng/ml po subkutanem bolusnem injiciranju (tmax: 25 minut).
Tiredness, chills, decreased appetite. 
utrujenost, mrazenje, zmanjšan apetit oslabelost
Skin reactions are mostly mild to moderate and usually resolve within a few days. 
Kožne reakcije so običajno blage do zmerne in izzvenijo v nekaj dneh.
If you use more LITAK than you should In case you inject an incorrect dose, tell your doctor immediately. 
Če ste uporabili večji odmerek zdravila LITAK, kot bi smeli V primeru, da ste si injicirali nepravilni odmerek, o tem nemudoma obvestite svojega zdravnika.
After subcutaneous bolus injection of a 0.14 mg/kg cladribine dose, a Cmax of 91 ng/ml is reached on average after 20 minutes only. 
Po subkutanem bolusnem injiciranju odmerka 0,14 mg/kg kladribina je Cmax 91 ng/ml dosežena po povprečno samo 20 minutah.
Forty percent of the patients who were treated with LITAK at a dose of 0.7 mg/kg body weight per cycle suffered from infections. 
Pri štiridesetih odstotkih bolnikov, zdravljenih z zdravilom LITAK v odmerku 0,7 mg/kg telesne mase na cikel, so se pojavile okužbe.
Reduced ossification was observed at 1.0 mg/kg/day. 
Zmanjšano zakostenevanje so opažali pri 1,0 mg/kg/dan.
LITAK has a major effect on the ability to drive and use machines. 
Zdravilo LITAK ima pomemben vpliv na sposobnost vožnje in upravljanja strojev.
LITAK is indicated for the treatment of hairy cell leukaemia. 
Zdravilo LITAK je indicirano za zdravljenje dlakavocelične levkemije.
The risk of severe myelotoxicity and long-lasting immunosuppression is increased in patients with a disease-related bone marrow infiltration or a previous myelosuppressive treatment. 
Tveganje hude mielotoksičnosti in dolgotrajne imunosupresije je povečano pri bolnikih z infiltracijo kostnega mozga, povezano z boleznijo, ali predhodnim mielosupresivnim zdravljenjem.
Avoid contact by pregnant women. 
Nosečnice naj se stiku izogibajo.
Do not use LITAK if you notice that the vial is damaged or that the solution is not clear or contains any particles. 
Ne uporabljajte zdravila LITAK, če opazite, da je viala poškodovana ali da raztopina ni bistra ali vsebuje kakršne koli delce.
In patients with a high tumour burden, prophylactic allopurinol therapy to control serum levels of uric acid, together with adequate or increased hydration, should be commenced 24 hours before the start of chemotherapy. 
Pri bolnikih z velikim tumorskim bremenom moramo uvesti preventivno zdravljenje z alopurinolom za nadzor serumskih koncentracij sečne kisline, skupaj z zadostno ali povečano hidracijo, 24 ur pred začetkom kemoterapije.
Additional followup and evaluation may be warranted if no alternative diagnosis can be established. 
Če ni mogoče postaviti alternativne diagnoze, sta upravičena dodatno spremljanje in diagnostika.
Uncommon: conjunctivitis Very rare: blepharitis 
Občasni: konjunktivitis Zelo redki: blefaritis
In 7- to 14-day continuous intravenous infusion studies in cynomolgus monkeys, the target organs were the immune system ( 0.3 mg/kg/day), bone marrow, skin, mucous membranes, nervous system and testes ( 0.6 mg/kg/day) and kidneys ( 1 mg/kg/day). 
V študijah neprekinjene 7- do 14-dnevne intravenske infuzije pri opicah Cynomolgus so bili tarčni organi imunski sistem ( 0,3 mg/kg/dan), kostni mozeg, koža, sluznice, živčevje in moda ( 0,6 mg/kg/dan) ter ledvice ( 1 mg/kg/dan).
Gastrointestinal adverse reactions like nausea (5-28%), vomiting (1-13%), and diarrhoea (3-12%) as well as fatigue (2-48%), headache (1-23%), and decreased appetite (1-22%) have been reported during treatment with cladribine. 
Med zdravljenjem s kladribinom so poročali o neželenih učinkih v prebavilih, kot so slabost (5-28 %), bruhanje (1-13 %) in diareja (3-12 %), pa tudi utrujenost (2-48 %), glavobol (1-23 %) in zmanjšan apetit (1-22 %).
- one sterile syringe (e.g. 10 ml LUER syringe), 
- eno sterilno brizgo (npr. 10 ml LUER brizgo),
Pancytopenia is normally reversible and the intensity of bone marrow aplasia is dose-dependent. 
Pancitopenija je običajno obrnljiva, jakost aplazije kostnega mozga pa je odvisna od odmerka.
Like other nucleoside analogues, treatment with cladribine is associated with myelosuppression and profound and prolonged immunosuppression. 
Kot pri drugih nukleozidnih analogih, je tudi zdravljenje s kladribinom povezano z mielosupresijo ter globoko in podaljšano imunosupresijo.
Rare: Cardiac failure, atrial fibrillation, cardiac decompensation 
Redki: srčno popuščanje, atrijska fibrilacija, dekompenzacija srca
Secondary malignancies are expected to occur in patients with hairy cell leukaemia. 
Pojav sekundarnih malignomov pri bolnikih z dlakavocelično levkemijo pričakujemo.
Since interactions with medicinal products undergoing intracellular phosphorylation, such as antiviral agents, or with inhibitors of adenosine uptake may be expected, their concomitant use with cladribine is not recommended. 
Ker lahko pričakujemo medsebojna delovanja z zdravili, ki so podvržena znotrajcelični fosforilaciji, kot so protivirusne učinkovine, ali z zaviralci privzema adenozina, njihova sočasna uporaba s kladribinom ni priporočena.
If someone else is injecting you, they can also use the outer surface of the upper arms or the buttocks. 
Če vam injicira kdo drug, lahko injicira tudi v zunanjo površino nadlakta ali v zadnjico.
The recommended dose is directly withdrawn by a syringe and injected as a subcutaneous bolus injection without dilution. 
Priporočeni odmerek neposredno odvzamemo z injekcijsko brizgo in injiciramo v obliki podkožne bolusne injekcije brez redčenja.
The renal excretion of unmetabolised cladribine occurs within 24 hours and accounts for 15% and 18% of the dose after 2-hour intravenous and subcutaneous administration, respectively. 
Ledvično izločanje nepresnovljenega kladribina se pojavi v 24 urah in predstavlja 15 % oziroma 18 % odmerka po 2-urni intravenskem oziroma subkutanem dajanju.
Due to a potential increase of haematological toxicity and bone marrow suppression, cladribine must not be used concomitantly with other myelosuppressive medicinal products. 
Zaradi možnega povečanja hematološke toksičnosti in zaviranja delovanja kostnega mozga kladribina ne smemo uporabljati sočasno z drugimi mielosupresivnimi zdravili.
The single substitution of hydrogen for chlorine at position 2 distinguishes cladribine from its natural counterpart 2'-deoxyadenosine and renders the molecule resistant to deamination by adenosine deaminase. 
Ena sama substitucija vodika za klor na mestu 2 razlikuje kladribin od svojega naravnega dvojnika 2'-deoksiadenozina in tvori molekulo, odporno proti deaminaciji z adenozinsko deaminazo.
LITAK is a cytotoxic and should therefore be handled with caution. 
Zdravilo LITAK je citotoksično, zato morate z njim ravnati previdno.
The mechanism of action of cladribine is attributed to the incorporation of CdATP into DNA strands: the synthesis of new DNA in dividing cells is blocked and the DNA repair mechanism is inhibited, resulting in an accumulation of DNA strand breaks and a decrease of NAD (nicotinamide adenine dinucleotide) and ATP concentration, even in resting cells. 
Mehanizem delovanja kladribina pripisujemo vgrajevanju CdATP v verige DNA: tvorba nove DNA v delečih se celicah je onemogočena, zavrt je tudi mehanizem popravljanja DNA, kar povzroči kopičenje prelomov verige DNA in znižanje koncentracij NAD (nikotinamid adenin dinukleotid) in ATP tudi v mirujočih celicah.
Procedures for proper handling and disposal of antineoplastic medicinal products should be used. 
Uporabljati je treba postopke za ustrezno ravnanje in odlaganje zdravil z delovanjem na novotvorbe.
Cladribine is an antineoplastic and immunosuppressive substance that can induce considerable toxic adverse reactions, such as myelo- and immunosuppression, long-lasting lymphocytopenia, and opportunistic infections. 
Kladribin je antineoplastična in imunosupresivna učinkovina, ki lahko povzroči znatne toksične neželene učinke, kot so mielo- in imunosupresija, dolgotrajna limfocitopenija in oportunistične okužbe.
Warnings and precautions Talk to your doctor or pharmacist before using LITAK. 
Opozorila in previdnostni ukrepi Pred začetkom uporabe zdravila LITAK se posvetujte z zdravnikom ali farmacevtom.
The biexponential decline of the serum concentration of cladribine after subcutaneous bolus injection is comparable to elimination parameters after 2-hour intravenous infusion with an initial and terminal half-life of approximately 2 hours and 11 hours, respectively. 
Bieksponentni padec serumske koncentracije kladribina po subkutani bolusni injekciji je primerljiv z eliminacijskimi spremenljivkami po 2-urni intravenski infuziji z začetnim in terminalnim razpolovnim časom približno 2 uri oziroma 11 ur.
What do I need for the injection? 
Kaj potrebujem za injekcijo?
Elderly patients should be treated by individual assessment and careful monitoring of the blood counts and of the renal and hepatic function. 
Starejše bolnike je treba zdraviti po individualni oceni in s skrbnim spremljanjem krvne slike ter delovanja ledvic in jeter.
LITAK should be injected into the tissue just under the skin (subcutaneous injection). 
Zdravilo LITAK si injicirajte v tkivo tik pod kožo (subkutana injekcija).
Common: tachycardia, heart murmur, hypotension, epistaxis, myocardial ischemia * 
Pogosti: tahikardija, srčni šum, hipotenzija, epistaksa, ishemija miokarda *
Special handling precautions (see package leaflet) 
Posebna navodila za ravnanje (glej navodilo za uporabo).
Cladribine shows complete bioavailability after parenteral administration; the mean area under the plasma concentration versus time curve (AUC) is comparable after continuous or intermittent 2-hour intravenous infusion and after subcutaneous injection. 
Kladribin izkazuje popolno biološko razpoložljivost po parenteralnem dajanju; povprečna površina pod krivuljo koncentracije v odvisnosti od časa (AUC) je primerljiva po neprekinjeni ali intermitentni 2-urni intravenski infuziji in po subkutanem injiciranju.
Non-haematological adverse reactions are generally mild to moderate in severity. 
Nehematološki neželeni učinki so v splošnem blagi do zmerni.
Packs contain 1 or 5 vials, each with 5 ml of solution. 
Pakiranje vsebujejo 1 ali 5 vial, od katerih vsaka vsebuje 5 ml raztopine.
OUTER CARTON (1-VIAL PACK) 
ŠKATLA (PAKIRANJE Z 1 VIALO)
Remove the injection needle from the wrapping and place it firmly on the tip of the syringe. 
Iz ovitka vzemite injekcijsko iglo in jo trdno pritrdite na konico brizge.
There are no studies available using cladribine in patients with renal or hepatic impairment (see also section 4.2 and section 4.4). 
O uporabi kladribina pri bolnikih z okvarjenim delovanjem ledvic ali jeter ni nobenih študij (glej tudi poglavje 4.2 in poglavje 4.4).
Very rare: cholecystitis 
Zelo redki: holecistitis
Cytotoxic medicinal products should be handled with caution. 
S citotoksičnimi zdravili je treba ravnati previdno.
The mean plasma clearance amounts to 794 ml/min after intravenous infusion and to 814 ml/min after subcutaneous bolus injection at a dose of 0.10 mg/kg body weight/day. 
Povprečni plazemski očistek je 794 ml/min po intravenski infuziji in 814 ml/min po subkutani bolusni injekciji v odmerku 0,10 mg/kg telesne mase/dan.
Cladribine is a cytotoxic medicinal product, which is mutagenic to cultured mammalian cells. 
Kladribin je citotoksično zdravilo, ki je mutageno za sesalske celice v kulturah.
Very common severe complications, in some cases with fatal outcome, are opportunistic infections (e.g. Pneumocystis carinii, Toxoplasma gondii, listeria, candida, herpes viruses, cytomegalovirus and atypical mycobacteria). 
Zelo pogosti hudi zapleti, v nekaterih primerih s smrtnim izidom, so oportunistične okužbe (npr. Pneumocystis carinii, Toxoplasma gondii, Listeria, Candida, herpes virusi, citomegalovirus in atipična mikobakterija).
Uncommon: somnolence, paraesthesia, lethargy, polyneuropathy, confusion, ataxia 
Občasni: zaspanost, parestezije, letargija, polinevropatija, zmedenost, ataksija
OUTER CARTON (5-VIAL PACK) 
ŠKATLA (PAKIRANJE S 5 VIALAMI)
The intracellular retention time of cladribine nucleotides in vivo is clearly prolonged as compared to the retention time in the plasma: Half-lives t1/2 of initially 15 hours and subsequently more than 30 hours were measured in leukaemic cells. 
Znotrajcelični retencijski čas kladribinovih nukleotidov in vivo je jasno podaljšan v primerjavi z retencijskim časom v plazmi: v levkemičnih celicah so izmerili razpolovne čase t1/2 ob začetku 15 ur in kasneje več kot 30 ur.
Patients undergoing treatment with cladribine should be closely monitored for signs of haematologic and non-haematologic toxicities. 
Bolnike, ki jih zdravimo s kladribinom, moramo skrbno spremljati za primer pojava znakov hematoloških in nehematoloških toksičnosti.
Patients with active infection should be treated for the underlying condition prior to receiving therapy with cladribine. 
Bolnike z aktivno okužbo je treba pred prejemanjem zdravljenja s kladribinom zdraviti za predhodno okužbo.
In rabbits, cladribine is teratogenic at doses of 3.0 mg/kg/day (given on gestation days 7-19). 
Pri kuncih je kladribin teratogen v odmerkih 3,0 mg/kg/dan (danih na dneve gestacije 7-19).
Effects on sternal ossification were seen at 1.5 and 3.0 mg/kg/day. 
Učinke na zakostenevanje prsnice so opažali pri 1,5 in 3,0 mg/kg/dan.
After injecting the liquid, remove the needle. 
Po injiciranju tekočine iglo izvlecite.
How to use LITAK 
Kako uporabljati zdravilo LITAK
Cladribine is eliminated mainly by the kidneys. 
Kladribin se izloča predvsem preko ledvic.
What LITAK looks like and contents of the pack LITAK is available in glass vials containing 5 ml of clear, colourless solution for injection. 
Zdravilo LITAK je na voljo v steklenih vialah, ki vsebujejo 5 ml bistre, brezbarvne raztopine za injiciranje.